Amazon’s AI Chips Outperform Nvidia in Biotech Applications, Metagenomi Shares Drop
Amazon's AWS Inferentia 2 accelerators have demonstrated superior performance in biotech applications, surpassing Nvidia's chips in speed and cost-efficiency. Metagenomi, a gene-editing firm, reported a 56% reduction in costs after switching to Amazon's technology. Despite this advancement, Metagenomi's shares fell 7% following the announcement.
The adoption of AWS Inferentia marks a significant expansion beyond traditional AI applications like chatbots and voice assistants. Metagenomi leverages CRISPR technology, a Nobel Prize-winning method, to develop gene-editing therapies. However, the market reaction suggests investor skepticism or broader sector pressures.